Navigation Links
Scientists link fragile X tremor/ataxia syndrome to binding protein in RNA
Date:8/15/2007

Scientists have discovered a key protein in the toxic brain pathway that leads to fragile X tremor/ataxia syndrome (FXTAS), an inherited neurodegenerative disorder. The finding, in a Drosophila (fly) model of FXTAS, could help unravel the complex mechanisms of FXTAS and lead scientists to develop therapies to target the protein. The research will be published in the Aug. 16 issue of the journal Neuron.

Fragile X tremor/ataxia syndrome was first recognized several years ago as a neurodegenerative disease caused by a premutation in carriers of the mutated FMR1 gene, the same gene that causes fragile X syndrome--the most common inherited cause of mental retardation. Individuals with the FMR1 premutation (a less exaggerated form of the mutation) do not have retardation, but instead are at risk for developing FXTAS, usually after age 50, causing progressive problems with movement (ataxia), tremor, memory loss, loss of sensation in the lower extremities (peripheral neuropathy), and mental and behavioral changes.

Fragile X syndrome occurs when a region of the FMR1 gene repeats a particular sequence of three DNA basesCGG--causing silencing of the FMRP protein. Called a trinucleotide repeat, this CGG sequence repeats only about 6 to 55 times in normal individuals, but between 200 and 1,000 times in those with fragile X syndrome.

In those with the premutation of the FMR1 gene, CGG repeats between 60 and 100 times.

Scientists estimate the frequency of fragile X syndrome as approximately 1 in 4,000 males and 1 in 8,000 females and the frequency of the FMR1 premutation as 1 in 800 males and 1 in 260 females. Approximately 20 percent of males with the permutation develop FXTAS. Approximately 20 percent of women with the premutation have premature ovarian failure a loss of ovarian function in women younger than 40.

Lead authors of the current study are Peng Jin, PhD, assistant professor of human genetics and Stephen T. Warren, PhD, Timmie professor and chair of human genetics at Emory University School of Medicine. Dr. Warren and his colleagues led an international team that discovered the FMR1 gene in 1991, later characterized the FMRP protein, and developed diagnostic tests for fragile X syndrome.

Drs. Jin and Warren earlier discovered (Neuron, 2003) that FXTAS is caused by elongated repeats of the CGG sequence in cells' RNA the molecules that translate the genetic code from DNA into proteins. In the current Neuron paper, Dr. Jin describes his discovery that the pur alpha protein, which is necessary for neuronal function and is involved in brain synapses tied to movement, is bound by the CGG trinucleotide repeats located in the RNA of the FMR1 gene.

Drs. Jin and Warren believe that because the repeated CGG sequences bind and sequester the pur alpha protein, the protein is not available for its normal function in the parts of the brain responsible for movement. The researchers also found that the pur alpha protein bound to CGG repeats becomes part of toxic brain aggregates, called inclusions, found in patients with neurodegeneration.

"Now that we have discovered a protein that is depleted by RNA in the premutation gene, we will try to identify more specifically how depletion of this protein can cause neurodegeneration, and we can use our fly model to conduct drug screening and begin to develop therapeutic drugs that could overcome this problem," says Dr. Jin.


'/>"/>

Contact: Holly Korschun
hkorsch@emory.edu
404-727-3990
Emory University
Source:Eurekalert

Related biology news :

1. Wisconsin scientists grow critical nerve cells
2. Scientists ID molecular switch in liver that triggers harmful effects of saturated and trans fats
3. UCSB scientists probe sea floor venting to gain understanding of early life on Earth
4. UAB scientists discover the origin of a mysterious physical force
5. Fox Chase Cancer Center scientists identify immune-system mutation
6. Scientists Replicate Hepatitis C Virus in Laboratory
7. Scientists detect probable genetic cause of some Parkinsons disease cases
8. Scientists find missing enzyme for tuberculosis iron scavenging pathway
9. Scientists seek answers on what activates deadly anthrax spores
10. Yale Scientists Find MicroRNA Regulates Ras Cancer Gene
11. Scientists collaborate to assess health of global environment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
(Date:3/29/2016)... Florida , March 29, 2016 ... the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased ... in ink used in a variety of writing instruments, ... Buyers of originally created collectibles from athletes on LegacyXChange ... forensic analysis of the DNA. Bill ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... Brooklyn, NY (PRWEB) , ... June 24, 2016 , ... ... 15mm, machines such as the Cary 5000 and the 6000i models are higher end ... height is the height of the spectrophotometer’s light beam from the bottom of the ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
Breaking Biology Technology: